Bone Density Conservation Agents/therapeutic use; Diagnosis, Differential; Diphosphonates/therapeutic use; Drug Administration Schedule; Humans; Imidazoles/therapeutic use; Osteitis Deformans/diagnosis/drug therapy/epidemiology; Treatment Outcome
Abstract :
[en] Paget's disease of bone (PDB) is a potentially crippling condition. Pain, fracture, spinal stenosis, nerve entrapment, vascular steal syndrome, secondary osteoarthritis, bone deformity, dental problems, deafness, excessive bleeding during orthopaedic surgery, rare sarcomatous degeneration, and hypercalcaemia constitute complications that may impair the quality of life. The therapeutic approach varies from symptomatic (analgesics, anti-inflammatory drugs) to more specific drugs such as increasingly potent bisphosphonates. Studies such as the PRISM study should in the future help to determine the superiority or not of aggressive treatment over symptomatic treatment in the prevention of complications. Various oral and/or intravenous (i.v.) bisphosphonates have been tested and are currently on the market. The most recently available nitrogen-containing bisphosphonate, i.v. zoledronic acid, is the most potent therapy available for the treatment of PDB. Its therapeutic efficacy, its long-term effect on biologic activity and its good tolerance currently supports its use as a first-line therapeutic option in patients suffering from PDB.
Disciplines :
General & internal medicine
Author, co-author :
Devogelaer, Jean-Pierre
Bergmann, Pierre
Body, Jean-Jacques
Boutsen, Y.
Goemaere, S.
Kaufman, J.-M.
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Rozenberg, S.
Boonen, S.
Language :
English
Title :
Management of patients with Paget's disease: a consensus document of the Belgian Bone Club.
Publication date :
2008
Journal title :
Osteoporosis International
ISSN :
0937-941X
eISSN :
1433-2965
Publisher :
Springer Science & Business Media B.V., Godalming, United Kingdom
Paget, J., On a form of chronic inflammation of bones (Osteitis Deformans) (1877) Med Chir Trans Lond, 60, pp. 37-63
Hosking, D., Meunier, P.J., Ringe, H.D., Reginster, J.-Y., Gennari, C., Fortnightly review: Paget's disease of bone: Diagnosis and management (1996) Br Med J, 312, pp. 491-494
Delmas, P.D., Meunier, P.J., Drug therapy: The management of Paget's disease of bone (1997) N Engl J Med, 336, pp. 558-566
Lyles, K.W., Siris, E.S., Singer, F.R., Meunier, P.J., Perspective. a clinical approach to diagnosis and management of Paget's disease of bone (2001) J Bone Miner Res, 16, pp. 1379-1387. , 8
Selby, P.L., Davie, M.W.J., Ralston, S.H., Stone, M.D., Guidelines on the management of Paget's disease of bone (2002) Bone, 31, pp. 10-19. , 3
Scarsbrook, A., Brown, M., Wilson, D., UK guidelines on management of Paget's disease of bone (2004) Rheumatology, 43, pp. 399-400
Langston, A.L., Ralston, S.H., Management of Paget's disease of bone (2004) Rheumatology, 43, pp. 955-959
Whyte, M.P., Paget's disease of bone (2006) N Engl J Med, 355, pp. 593-600
Acute pain management: Operative or medical procedures and trauma. Clinical Practice Guidelines n°1 (1993) AHCPR Publication # 92-0023, p. 107. , US Department of Health and Human Services. Agency for Health care policy and research
Devogelaer, J.P., Nagant De Deuxchaisnes, C., Hochberg, M.C., Silman, A.J., Smolen, J.S., Weinblatt, M.E., Weisman, M.H., Paget's disease of bone (2003) Rheumatology, Vol 2, pp. 2139-2147. , 3 Mosby London
Barker, D.J., Clough, P.W., Guyer, P.B., Gardner, M.J., Paget's disease of bone in 14 British towns (1977) Br Med J, 1, pp. 1181-1183
Cooper, C., Schafheutle, K., Dennison, E., Kellingray, S., Guyer, P., Barker, D., The epidemiology of Paget's disease in Britain: Is the prevalence decreasing ? (1999) J Bone Miner Res, 14, pp. 192-197
Cundy, H.R., Gamble, G., Wattie, D., Rutland, M., Cundy, T., Paget's disease of bone in New Zealand: Continued decline in disease severity (2004) Calcif Tissue Int, 75, pp. 358-364
Morales-Piga, A.A., Bachiller-Corral, F.J., Abraira, V., Beltran, J., Rapado, A., Is clinical expressiveness of Paget's disease of bone decreasing ? (2002) Bone, 30, pp. 399-403
Rapado, A., Jimenez, J., Morales, A., Carbonell, J., Del Pino, J., Patterns of diagnosis of Paget's disease in Spain (1999) J Bone Miner Res, 14, pp. 96-S98. , Suppl 2
Tiegs, R.D., Lohse, C.M., Wollan, P.C., Melton, L.J., Long-term trends in incidence of Paget's disease of bone (2000) Bone, 27, pp. 423-427
Gennari, L., Di Stefano, M., Merlotti, D., Prevalence of Paget's disease of bone in Italy (2005) J Bone Miner Res, 20, pp. 1845-1850
Detheridge, F.M., Guyer, P.B., Barker, D.J.P., European distribution of Paget's disease of bone (1982) Br Med J, 285, pp. 1005-1008
Lucas, G.J.A., Daroszewskia, A., Ralston, S.H., Contribution of genetic factors to the pathogenesis of Paget's disease of bone and related disorders (2006) J Bone Miner Res, 21, pp. 31-P37. , Suppl 2
Collins, D.H., Paget's disease of bone. Incidence and subclinical forms (1956) Lancet, 2, pp. 51-57
Altman, R.D., Musculoskeletal manifestations of Paget's disease of bone (1980) Arthritis Rheum, 23, pp. 1121-1127
Fernandez, S., Tiessen, L., Powell-Tuck, J., Beck, S., Johansen, A., Pagetic hip fracture. How big is the problem? (2007) Osteoporos Int, 18, p. 292. , Suppl 3
Sundaram, M., Imaging of Paget's disease and fibrous dysplasia (2006) J Bone Miner Res, 21, pp. 28-P30. , Suppl 2
Maldague, B., Malghem, J., Dynamic radiologic patterns of Paget's disease of bone (1987) Clin Orthop, 217, pp. 126-151
Meunier, P.J., Vignot, E., Therapeutic strategy in Paget's disease of bone (1995) Bone, 17, pp. 489S-491S. , Suppl 5
Siris, E.S., Lyles, K.W., Singer, F.R., Meunier, P.J., Medical management of Paget's disease of bone. Indications for treatment and review of current therapies (2006) J Bone Miner Res, 21, pp. 94-P98. , suppl 2
Nagant De Deuxchaisnes, C., Devogelaer, J.P., Simon, L., Sébert, J.L., Hérisson, C., Surveillance et suivi à long terme de la maladie osseuse de Paget (1989) La Maladie Osseuse de Paget: Actualités, , Masson Paris
Kanis, J.A., (1998) Pathophysiology and Treatment of Paget's Disease of Bone, , 2 Dunitz London
Van Staa, T.P., Selby, P., Leufkens, H.G.M., Lyles, K., Sprafka, J.M., Cooper, C., Incidence and natural history of Paget's disease of bone in England and Wales (2002) J Bone Miner Res, 17, pp. 465-471
Gold, D.H., Burchett, B.M., Shipp, K.M., Pieper, C.F., Lyles, K.W., Factors associated with self-rated health in patients with Paget's disease of bone (1999) J Bone Miner Res, 14, pp. 99-102. , Suppl 2
Ralston, S.H., Langston, A.L., Campbell, M.K., MacLennan, G., Selby, P.L., Fraser, W.D., Initial results from the PRISM study: A large randomised comparative trial of intensive versus symptomatic treatment for Paget's disease (2006) J Bone Miner Res, 21, p. 1. , Suppl 1
Langston, A.L., Campbell, M.K., Fraser, W.D., MacLennan, G., Selby, P., Ralston, S.H., Clinical determinants of quality of life in Paget's disease (2007) Calcif Tissue Int, 80, pp. 1-9. , PRISM Trial Group
Russell, R.G., Smith, R., Preston, C., Walton, R.J., Woods, C.G., Diphosphonates in Paget's disease (1974) Lancet, 1, pp. 894-898
Garnero, P., Gineyts, E., Schaffer, A.V., Seaman, J., Delmas, P.D., Measurement of urinary excretion of nonisomerized and b-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease (1998) Arthritis Rheum, 41, pp. 354-360
Reid, I.R., Davidson, J.S., Wattie, D., Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone (2004) Bone, 35, pp. 224-230
Shankar, S., Hosling, D.J., Biochemical assessment of Paget's disease of bone (2006) J Bone Miner Res, 21, pp. 22-P27. , Suppl 2
Installe, J., Nzeusseu, A., Bol, A., Depresseux, G., Devogelaer, J.P., Lonneux, M., 18F-fluoride PET for monitoring therapeutic response in Paget's disease of bone (2005) J Nucl Med, 46, pp. 1650-1658
Nagant De Deuxchaisnes, C., Maldague, B., Malghem, J., Devogelaer, J.P., Huaux, J.P., Rombouts-Lindemans, C., The action of the main therapeutic regimes on Paget's disease of bone, with a note on the effect of vitamin D deficiency (1980) Arthritis Rheum, 23, pp. 1215-1234
Margiloff, L., Harris, S.S., Lee, S., Lechan, R., Dawson-Hughes, B., Vitamin D status of an outpatient clinic population (2001) Calcif Tissue Int, 69, pp. 263-267
Chapuy, M.-C., Zucchelli, P., Meunier, P.J., La fonction parathyroïdienne dans la maladie osseuse de Paget (1982) Rev Rhum Mal Osteoartic, 49, pp. 99-102
Siris, E.S., Clemens, T.P., McMahon, D., Gordon, A., Jacobs, T.P., Canfield, R.E., Parathyroid function in Paget's disease of bone (1989) J Bone Miner Res, 4, pp. 75-79
Fenton, A.J., Gutteridge, D.H., Kent, G.N., Intravenous aminobisphosphonate in Paget's disease: Clinical, biochemical, histomorphometric and radiological responses (1991) Clin Endocrinol (Oxf), 34, pp. 197-204
Frijlink, W., Bijvoet, O., Te Velde, J., Heynen, G., Treatment of Paget's disease with 3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.) (1979) Lancet, 1, pp. 799-803
Siris, E., Paget's disease of bone (1995) J Clin Endocrinol Metab, 80, pp. 335-338
Boonen, S., Lips, P., Bouillon, R., Bischoff-Ferrari, H.A., Vanderschueren, D., Haentjens, P., Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: Evidence from a comparative metaanalysis of randomized controlled trials (2007) J Clin Endocrinol Metab, 92, pp. 1415-1423
Derose, J., Singer, F.R., Avramides, A., Response of Paget's disease to porcine and salmon calcitonins: Effects of long-term treatment (1974) Am J Med, 56, pp. 858-866
Devogelaer, J.P., Modern therapy for Paget's disease of bone. Focus on bisphosphonates (2002) Treat Endocrinol, 1, pp. 241-257
Delmas, P., Meunier, P.J., The management of Paget's disease of bone (1997) N Engl J Med, 336, pp. 558-566
Siris, E., Canfield, R., Jacobs, T., Stoddart, K., Spector, T., Clinical and biochemical effects of EHDP in Paget's disease of bone: Patterns of response to initial treatment and to long-term therapy (1981) Metab Bone Dis Relat Res, 3, pp. 301-308
Canfield, R., Rosner, W., Skinner, J., Diphosphonate therapy of Paget's disease of bone (1977) J Clin Endocrinol Metab, 44, pp. 96-106
Khairi, M.R.A., Altman, R.D., Derosa, G.P., Zimmermann, J., Schenk, R.K., Johnston, C.C., Sodium etidronate in the treatment of Paget's disease of bone. a study of long-term results (1977) Ann Intern Med, 87, pp. 656-663
Altman, R.D., Long-term follow-up of therapy with intermittent etidronate disodium in Paget's disease of bone (1985) Am J Med, 79, pp. 583-590
Yates, A.J.P., Percival, R.C., Gray, R.E.S., Intravenous clodronate in the treatment and retreatment of Paget's disease of bone (1985) Lancet, 1, pp. 1474-1477
Siris, E.S., Chines, A.A., Altman, R.D., Risedronate in the treatment of Paget's disease of bone: An open label, multicenter study (1998) J Bone Miner Res, 13, pp. 1032-1038
Reid, I., Nicholson, G.C., Weinstein, R., Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial (1996) Am J Med, 101, pp. 341-348
Gray, R.E.S., Yates, A.J.P., Preston, C.J., Smith, R., Russell, R.G.G., Kanis, J.A., Duration of effect of oral diphosphonate therapy in Paget's disease of bone (1987) Q J Med, 64, pp. 755-767
Siris, E., Weinstein, R.S., Altman, R., Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone (1996) J Clin Endocrinol Metab, 81, pp. 961-967
Roux, C., Gennari, C., Farrerons, J., Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone (1995) Arthritis Rheum, 38, pp. 851-858
Peris, P., Alvarez, L., Vidal, S., Martinez, M.A., Monegal, A., Guañabens, N., Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy (2007) Clin Exp Rheum, 25, pp. 206-210
Miller, P.D., Brown, J.P., Siris, E.S., Hoseyni, M.S., Axelrod, D.W., Bekker, P.J., A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone (1999) Am J Med, 106, pp. 513-520. , for the Paget's risedronate/etidronate study group
Thiebaud, D., Jaeger, P., Jacquet, A.F., Burckhardt, P., Une perfusion unique de pamidronate (APD) dans la maladie de Paget de l'os (1989) Schweiz Med Wochenschr, 119, pp. 71-74
Adamson, B.B., Gallacher, S.J., Byars, J., Ralston, S.H., Boyle, I.T., Boyle, B.F., Mineralisation defects with pamidronate therapy for Paget's disease (1993) Lancet, 342, pp. 1459-1460
Bombassei, G.J., Yocono, M., Raisz, L.G., Effects of intravenous pamidronate therapy on Paget's disease of bone (1994) Am J Med Sci, 308, pp. 226-233
Reid, I.R., Miller, P., Lyles, K., Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease (2005) N Engl J Med, 353, pp. 898-908
Markowitz, G.S., Fine, P.L., Stack, J.I., Toxic acute tubular necrosis following treatment with zoledronate (Zometa) (2003) Kidney Int, 64, pp. 281-289
Hosking, D., Lyles, K., Brown, J., Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate (2007) J Bone Miner Res, 22, pp. 142-148
Lecompte, P., Devogelaer, J.P., Kaufman, J.M., Goemaere, S., Geusens, P., Engbersen, A., Cost-effectiveness analysis of Aclasta in Paget's disease of bone in Belgium (2005) Value Health, 8, p. 73
Kurth, A.A., Kotowa, W., Goel, D., Maiwenn, J.A., Long-term cost-effectiveness of zoledronic acid versus risedronate in patients with Paget's disease of the bone in Germany (2006) Value Health, 9, p. 220. , 6
